Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation Journal Article
| Authors: | Iyengar, V.; Patell, R.; Ren, S.; Ma, S.; Pinson, A.; Barnett, A.; Elavalakanar, P.; Kazi, D. S.; Neuberg, D.; Zwicker, J. I. |
| Article Title: | Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation |
| Abstract: | Whether thrombocytopenia substantively increases the risk of hemorrhage associated with anticoagulation in patients with atrial fibrillation (AF) is not established. The purpose of this study was to compare rates of bleeding in patients with AF and thrombocytopenia (platelet count < 100 000/μL) to patients with AF and normal platelet counts (>150 000/μL). We performed a propensity score–matched, retrospective cohort study of adults (n = 1070) with a new diagnosis of AF who received a prescription for an oral anticoagulant between 2015 and 2020. The thrombocytopenia cohort was defined as having at least 2 platelet counts <100 000/μL on separate days in the period spanning the 12 weeks preceding the initiation of anticoagulation to 6 weeks after the initiation of anticoagulation. The primary end point was the 1-year cumulative incidence of major bleeding; secondary end points included clinically relevant bleeding, arterial and venous thrombotic events, and all-cause mortality. Patients with AF and thrombocytopenia experienced a higher 1-year cumulative incidence of major bleeding (13.3% vs 5.7%; P < .0001) and clinically relevant bleeding (24.5% vs 16.7%; P = .005) than the controls. Thrombocytopenia was identified as an independent risk factor for major bleeding (hazard ratio, 2.20; confidence interval, 1.36-3.58; P = .001), with increasing risk based on the severity of thrombocytopenia. The cumulative incidence of arterial thrombosis at 1 year was 3.6% in the group with thrombocytopenia and 1.5% in controls (Gray test, P = .08). These findings suggest that baseline platelet counts are an important biomarker for hemorrhagic outcomes in AF and that the degree of thrombocytopenia is an important factor in determining the level of risk. © 2023 by The American Society of Hematology. |
| Keywords: | adult; major clinical study; thrombocytopenia; cohort analysis; retrospective study; risk factor; vein thrombosis; atrial fibrillation; artery thrombosis; vascular disease; platelet count; anticoagulant agent; clinical outcome; propensity score; human; male; female; article; all cause mortality |
| Journal Title: | Blood Advances |
| Volume: | 7 |
| Issue: | 24 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-12-26 |
| Start Page: | 7516 |
| End Page: | 7524 |
| Language: | English |
| DOI: | 10.1182/bloodadvances.2023011235 |
| PUBMED: | 37756539 |
| PROVIDER: | scopus |
| PMCID: | PMC10761355 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Jeffrey Zwicker -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work